Saturn V Capital Management LP 13F holdings, Q1 2025
Holdings as of March 31, 2025 · filings on SEC EDGAR · latest filing →
Saturn V Capital Management LP disclosed 21 US equity positions worth $198.2m in its Q1 2025 13F filing. The largest position was ASND at 15.7% of the reported book, followed by IRON and CGON. Against the Q4 2024 filing, it opened 1 new position, added to 10 and reduced 8 among the top 21 holdings.
What did Saturn V Capital Management LP own in Q1 2025? Top 21 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2024 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A/S | Healthcare | 15.7% | $31.1m | 199,264 | 0% | held |
| 2 | IRON DISC MEDICINE INC | Healthcare | 13.0% | $25.7m | 518,177 | 2% | added |
| 3 | CGON CG ONCOLOGY INC | Healthcare | 7.1% | $14.1m | 577,696 | -3% | reduced |
| 4 | XENE XENON PHARMACEUTICALS INC | Healthcare | 7.0% | $13.9m | 413,711 | 28% | added |
| 5 | MERUS N V | 6.9% | $13.6m | 323,211 | 38% | added | |
| 6 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 6.8% | $13.4m | 343,849 | -1% | reduced |
| 7 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 6.5% | $12.8m | 1,041,280 | 5% | added |
| 8 | CELC CELCUITY INC | Healthcare | 5.6% | $11.1m | 1,093,677 | 3% | added |
| 9 | COGT COGENT BIOSCIENCES INC | Healthcare | 4.5% | $8.9m | 1,480,020 | -1% | reduced |
| 10 | PCVX VAXCYTE INC | Healthcare | 4.4% | $8.8m | 232,295 | 14% | added |
| 11 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 4.3% | $8.6m | 2,426,436 | 173% | added |
| 12 | ARGX ARGENX SE | Healthcare | 4.1% | $8.2m | 13,862 | -30% | reduced |
| 13 | CNTA CENTESSA PHARMACEUTICALS PLC | 3.3% | $6.5m | 448,692 | – | new | |
| 14 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 2.2% | $4.4m | 598,191 | 212% | added |
| 15 | CTNM CONTINEUM THERAPEUTICS INC | 2.0% | $3.9m | 560,979 | -2% | reduced | |
| 16 | ABVX ABIVAX SA | 1.7% | $3.5m | 552,926 | -15% | reduced | |
| 17 | 4XC1 KALVISTA PHARMACEUTICALS INC | 1.5% | $2.9m | 255,060 | -54% | reduced | |
| 18 | NEWAMSTERDAM PHARMA COMPANY | 1.2% | $2.4m | 116,353 | 16% | added | |
| 19 | SLN SILENCE THERAPEUTICS PLC | 1.0% | $2.1m | 732,463 | 85% | added | |
| 20 | CRNXGBP CRINETICS PHARMACEUTICALS IN | 1.0% | $2.0m | 59,017 | -0% | held | |
| 21 | INOZYME PHARMA INC | 0.2% | $454.3k | 499,254 | -64% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.